viernes, 13 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 23, 2026

Earnings live: Intel stock plunges, with more Big Tech earnings from Apple, Microsoft, and Tesla ahead

View original at finance.yahoo.com
“Overall revenue in the third quarter declined 10% year over year to $2.6 billion, missing Wall Street estimates of $2.7 billion, according to S&P Global Market Intelligence.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • While anticipated some moderation in client trading activity towards back end of year, instead saw acceleration in activity, which contributed to higher volume-related costs including performance-based compensation

    80% confidence
  • Doesn't see any real hurdles to resuming Grasberg mine operations as planned in Q2 2026

    80% confidence
  • Seeing sales growth in categories in US and Europe, albeit at a slower pace. Consumer is choosing to be more diligent in using pantry inventory and dosing products more carefully. None of this is untypical and won't sustain. Categories will return to 3-4% growth over time.

    80% confidence
  • Consumers, especially low- to middle-income households, continue to make more frequent trips to the store while purchasing fewer units per trip, a trend that started early in the year and accelerated through Q4

    80% confidence
  • The K-shaped economy powers trade-down in basics but trade-up within the more discretionary Beauty sub-sector

    80% confidence
  • Wall Street analysts estimate 8.2% increase in EPS for Q4 2025 for S&P 500. If that rate holds, it would represent the 10th consecutive quarter of annual earnings growth.

    80% confidence
  • The continued top-line strength for the core consumer segment is still a key differentiator for McCormick

    80% confidence
  • Company has confidence in plans to deliver stronger results in second half of fiscal year. Remains committed to integrated growth strategy and opportunity to reinvent P&G as the CPG company of the future.

    80% confidence
  • Grasberg mine closure impacted copper volumes by 10% for 2025 compared to forecasts

    80% confidence
  • Global inventories of copper on exchanges have risen in recent months during a period of sharp increases in copper prices. Most analysts project the market will be tightly balanced during 2026 with some projecting deficits and others small surpluses.

    80% confidence
  • Our fourth quarter and full year results reflect solid top line growth and strong and stable credit performance. Years of strategic preparation and our choices to consistently invest to sustain long-term growth and returns enable our results and put us in a strong position going forward.

    80% confidence
  • National security business continues to see good growth and prospects, and civil business is starting to reignite. The market feels like it's at an inflection point.

    80% confidence
  • The environment across key markets is marked by volatility and continued pressure from inflation, geopolitical and trade uncertainty, threat of rising unemployment, and overall consumer confidence remains low

    80% confidence
  • The company saw improvement in demand profile across every segment of the business, with premium and loyalty as biggest drivers, and positive trends in Main Cabin

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com
Earnings live: Intel stock plunges, with more Big Tech earnings from Apple, Microsoft, and Tesla ahead — Source | Via News | es.VIA.NEWS